Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Exclusion Criteria11

• Key Exclusion for all Participants:
• Following ocular disorders
• Current evidence of Grade 2 or higher corneal disorder
• Current evidence of active macular disorder (example, Age-related macular degeneration, central serous chorioretinal disease)
• Known to be human immunodeficiency virus (HIV) positive at Screening.
• A prolonged QT/QTc interval (\[QT interval using Fridericia's formula\] QTcF greater than (>) 480 millisecond \[ms\]) demonstrated on ECG.
• Any significant acute medical illness (such as new conditions or exacerbation of pre-existing conditions) within 8 weeks of dosing.
• Presence of severe ascites, edema, or uncontrolled hepatic encephalopathy
• The participant's standard therapy/concomitant medication for diseases related to hepatic disease has not remained stable/unchanged for at least two weeks before dosing of study drug.
• Syphilis as demonstrated by positive serology at Screening.
• Any abnormal finding based on physical examination, assessment of vital signs, ECG, or laboratory test results that requires treatment or clinical follow up based on investigators opinion.